Solid operational growth and improved profitability were achieved in H1 2026, with strong cash flow and robust demand for consumables and equipment. Guidance for full-year revenue and margins is confirmed, despite tariff-related uncertainties and delayed advanced therapy orders.Based on Sartorius S…
Solid operational growth and improved profitability in H1 2026, with strong cash flow and robust demand for consumables and equipment. Guidance for full-year revenue and margin is confirmed, despite tariff-related uncertainties and isolated delays in advanced therapies.Based on Sartorius Stedim Bio…
Operational sales growth reached 7.7% in H1 2026, with strong consumables demand and improved margins. Free cash flow and net profit rose sharply, while guidance for FY 2026 remains robust despite tariff-related uncertainties.Original document: Sartorius Stedim Biotech SA [DIM] Slides Release — Jul…
